To evaluate the shared genetic etiology of type 2 diabetes (T2D) and coronary heart disease (CHD), we conducted a genome-wide, multi-ancestry study of genetic variation for both diseases in up to 265,678 subjects for T2D and 260,365 subjects for CHD. We identify 16 previously unreported loci for T2D and 1 locus for CHD, including a new T2D association at a missense variant in HLA-DRB5 (odds ratio (OR) = 1.29). We show that genetically mediated increase in T2D risk also confers higher CHD risk. Joint T2D-CHD analysis identified eight variants-two of which are coding-where T2D and CHD associations appear to colocalize, including a new joint T2D-CHD association at the CCDC92 locus that also replicated for T2D. The variants associated with both outcomes implicate new pathways as well as targets of existing drugs, including icosapent ethyl and adipocyte fatty-acid-binding protein.
90,831 CHD cases and 169,534 controls to identify genetic pathways connected with both outcomes.
RESULTS

Genome-wide association and replication testing for T2D
We used genetic data from 48,437 individuals (13,525 T2D cases and 34,912 controls) of South Asian (n = 28,139; 9,654 T2D cases and 18,485 controls) and European (n = 20,298; 3,871 T2D cases and 16,427 controls) descent. We used non-overlapping data for T2D from the DIAGRAM Consortium 5 and conducted combined discovery analysis on 198,258 participants (48,365 T2D cases and 149,893 controls). Characteristics of the participants and information on genotyping quality control are summarized in Supplementary  Tables 1-3 and Supplementary Figure 1 . After removing known loci, we advanced into replication 21 new loci with suggestive association with T2D (P ≤ 5 × 10 −6 ). We performed further testing of these SNPs in additional samples of up to 67,420 individuals (24,972 cases and 42,448 controls) of South Asian (n = 13,960; 4,587 T2D cases and 9,373 controls), European (n = 2,479; 387 T2D cases and 2,092 controls), and East-Asian (n = 50,981; 19,998 T2D cases and 30,983 controls) descent. Our combined discovery and replication analyses included 265,678 participants (73,337 T2D cases and 192,341 controls) (Supplementary Fig. 1a ). In the combined analysis across both stages, 14 SNPs at previously unreported loci for T2D obtained genomewide significance (fixed-effects meta-analysis P < 5 × 10 −8 ; Table 1) . A previous report found one of our variants (rs10507349) strongly associated with T2D 9 , but we report genome-wide significance for this variant here for the first time. Population-specific analyses (Europeans only or South Asians only) identified one additional locus where a sentinel variant obtained genome-wide significance in only European participants ( Table 1 The global epidemic of T2D is expected to worsen over the coming decades, and the number of people with T2D is projected to reach ~592 million by 2035 (ref. 1) . T2D is also a major risk factor for CHD, which is the leading cause of death worldwide 2 . Patients with T2D are also at a twofold higher risk of mortality due to CHD as compared to individuals who do not have T2D 3 , although the mechanisms that link T2D with increased risk of CHD remain inadequately understood. Recently, a coding variant in the GLP1R gene encoding the glucagon-like peptide-1 receptor was reported 4 that was associated with lower fasting glucose levels, lower T2D susceptibility, and, more modestly, with reduced risk for CHD, a result consistent with existing therapeutic perturbation of this gene. This type of result is noteworthy and motivates the search for additional loci with this type of genetic support: associations with protective effects for both T2D and CHD in humans. Such targets would merit detailed molecular, functional, and therapeutic experimentation, but these candidate loci need to be first identified from existing and newly generated data sets.
Genome-wide association studies (GWAS) have advanced understanding of the genetic architecture individually for each disease, yielding discovery of several dozen loci for T2D and CHD 5, 6 . Previous work has also demonstrated a genetic correlation between these endpoints 7, 8 , although no study has directly compared individual variants beyond established sites across the genome or examined the pathways that are shared by the two outcomes. Regional association for multiple SNPs for both endpoints at a locus has been observed (for example, CDKN2A-CDKN2B or APOE) 5, 6 . These initial observations indicate that the genetic pathways that connect T2D and CHD may have a modest impact on disease risk, hence requiring large sample sizes to enable robust discovery.
We therefore assembled a discovery association set for T2D comprising 73,337 T2D cases and 192,341 controls to first enable discovery of new loci for T2D. Second, we used additional genetic data on was little evidence of heterogeneity of effect between the ancestry groups in either our primary genetic analyses or across the two stages (Supplementary Fig. 2 ). We replicated previously reported associations with T2D 5, 9 at 60 loci at genome-wide significance; a further 25 known loci were associated with T2D at P < 0.05 ( Fig. 1 and Supplementary Table 4) . We did not observe association at three loci (rs76895963, rs7330796, and rs4523957) in our overall metaanalyses, owing to their previous discovery in subjects of East Asian ancestry (Supplementary Table 4 10, 11 . These data suggest a candidate gene at two loci (ITFG3 and PLEKHA1) where the lead eQTL association strongly tagged the T2D association (r 2 = 1.0).
Coding variants at new genetic loci
To identify coding variants that may influence protein structure at unreported T2D loci, we obtained data on up to 31,207 individuals (9,500 T2D cases, 21,707 controls) of South Asian (7,832 T2D cases, 16,703 controls) and European origin (1,668 T2D cases, 5,004 controls) (Online Methods) genotyped on the ExomeChip 12 . We investigated 505 variants captured by the ExomeChip within ±250-kb regions flanking the sentinel SNPs. We identified one missense variant in HLA-DRB5 (rs701884) that was associated with T2D risk at close to exome-wide significance (fixed-effects meta-analysis P < 2 × 10 −7 ) (Supplementary Table 7 ). The missense variant was found to have a relatively stronger impact on disease risk than the lead noncoding variant. At HLA-DRB5, the OR for T2D for the missense variant (rs701884) was 1.29 (95% confidence interval (CI) = 1.23-1.35; P = 4.8 × 10 −7 ) as compared to the T2D OR of 1.06 (95% CI = 1.04-1.08; P = 7.56 × 10 −9 ) for the noncoding variant (rs2050188). Existing knowledge on gene function is summarized in Supplementary Table 8 .
Variant association with traits and circulating biomarkers
To help understand the underlying biological mechanisms, we examined the association of genetic variation at newly discovered loci with a range of phenotypes and biomarkers (n = 70 traits) (Supplementary Table 9 ). We also used an association screen against a panel of 105 phenotypic traits measured in the PROMIS study in up to 17,542 participants (Supplementary Table 10) 13 . For the new loci, we conducted 2,800 variant-phenotype analyses using linear regression resulting in a Bonferroni-adjusted significance threshold of P = 1.8 × 10 −5 . Allelic variation that increased T2D risk was associated at TMEM18 with increased body mass index (BMI; P = 4.39 × 10 −52 ), BMI in childhood (P = 7.95 × 10 −12 ), obesity (P = 2.50 × 10 −25 ) and obesity in childhood (P = 2.85 × 10 −20 ); at KL with increased fasting glucose (P = 2.26 × 10 −8 ); at PLEKHA1 with increased risk of neovascular disease (P = 2.71 × 10 −94 ); at SLC22A1 with increased lipoprotein(a) levels (P = 5.10 × 10 −6 ); and at CMIP with decreased HDL cholesterol (HDL-C) (P = 1.32 × 10 −19 ), increased triglycerides (P = 2.14 × 10 −7 ), and decreased adiponectin (P = 1.87 × 10 −18 ).
Genetic risk for T2D and CHD shared at established loci
We next examined the relationships of sentinel T2D SNPs with the risk of CHD at all T2D loci (Supplementary Table 11 ). For analyses in relation to CHD, we used data on up to 260,365 participants (90,831 CHD cases and 169,534 controls) (Online Methods). We found allelic variation at 17 T2D loci to be nominally associated with CHD risk at P < 0.01, which was more than expected (17 of 106 T2D SNPs; binomial test P = 5.9 × 10 −13 ). In one case, we found that the T2D sentinel SNP rs7578326 (the IRS1 locus) was associated with both T2D and CHD at genome-wide levels of significance (Supplementary  Table 11 and Supplementary Fig. 4 ). To the best of our knowledge, this is the first definitive report of genetic variation at IRS1 associated with CHD (Supplementary Note) 6 . We further investigated the relationship between these two endpoints in more detail.
Genetically elevated T2D risk overall increases CHD risk
First, we examined whether elevated T2D risk conferred a higher risk of CHD using the framework of Mendelian randomization (MR) [14] [15] [16] and examined whether all genetic T2D risk pathways influence CHD susceptibility in a similar way. We calculated genetic Table 14) . Finally, in contrast to these scores, variants associated with T2D and glucose or insulin-related traits, but not other traits, were not associated with CHD (OR = 1.07; Wald test P = 0.06) (Supplementary Table 14) ; however, this could be due to reduced power of this instrument relative to others, as has been observed previously 15 . These analyses indicate that pathways segregating genetic susceptibility for T2D may not have an equivalent impact on CHD risk.
Genetic risk for T2D and CHD shared across the genome
We next looked for enrichment in the consistency of the risk allele associated with both T2D and CHD across the genome. In our metaanalyses, of the 1,260 variants associated with T2D at P < 5 × 10 −8 , we found that 76.1% of the T2D risk alleles were associated with higher risk of CHD as well, in comparison with an expectation of 50% under the null hypothesis (binomial test P = 2.6 × 10 −33 ; Table 2 ). In contrast, variants associated with CHD at P < 5 × 10 −8 were not enriched for directional consistency in allelic associations with T2D (48.2 versus the 50% expected; binomial test P = 0.79). Among the loci nominally associated with T2D and CHD (P < 0.05 but excluding associations above P < 5 × 10 −8 ), 81.8% of the allelic variation associated with both the outcomes in a directionally consistent manner (binomial test P < 10 −100 ). Furthermore, of the allelic variation that was not associated with both T2D and CHD at P > 0.05, only 50.6% of the allelic variation (as compared to the 50% expected under the null hypothesis) was associated with the two outcomes in a directionally consistent manner ( Table 2) . To rule out any biases introduced as a result of allelic variations at a limited set of loci associated with both CHD and T2D, we conducted sensitivity analyses in PROMIS using genome-wide variants pruned for linkage disequilibrium (LD) and found results consistent for an overall enrichment of loci associated with both T2D and CHD in a directionally consistent manner (Supplementary Table 15 ).
Joint test identifies an additional locus for T2D and CHD
Motivated by the enrichment of directionally consistent associations of allelic variation between T2D and CHD SNPs, we performed a genome-wide association scan that modeled the joint distribution of association with both T2D and CHD (T2D-CHD; Online Methods), a test to help improve power for discovery of new loci that are associated with both the outcomes ( Supplementary Fig. 5 ). After verifying that our test statistic was calibrated ( Supplementary Fig. 6 ), we used this approach to identify a set of loci that were associated with both T2D and CHD (trait-specific fixed-effects meta-analysis P < 10 −3 ) and that were overall associated at genome-wide levels of significance (bivariate P < 5 × 10 −8 ; Supplementary Table 16) . Nineteen loci met these criteria, which included many established loci for T2D or CHD. We identified one association near CCDC92 (bivariate P = 2.7 × 10 −9 ; Supplementary Fig. 7a ). The sentinel variant (rs825476) was associated with both T2D (fixed-effects meta-analysis P = 2.2 × 10 −6 ) and CHD (fixed-effects meta-analysis P = 2.9 × 10 −7 ) ( Supplementary Fig. 7b ,c); rs825476[T] at this locus increased risk for both outcomes. To demonstrate conclusive association of rs825476 with T2D, we sought replication data from eight additional cohorts, comprising 21,560 T2D cases and 42,814 controls. We observed marginal replication for this variant in those data alone (OR = 1.04, 95% CI = 1.01-1.07; fixed-effects meta-analysis P = 5.5 × 10 −3 ) and obtained genome-wide significance when combined with the previous data (OR = 1.04, 95% CI = 1.03-1.06; fixed-effects meta-analysis P = 4.3 × 10 −8 ; Supplementary Fig. 7b ). Analyses conditioned on the lead SNP accounted for all the residual joint T2D-CHD association in the region (Online Methods), indicating that the underlying genetic associations for both endpoints colocalize to a shared genetic risk factor potentially tagged by the sentinel SNP (Supplementary Fig. 8 ). The rs825476[T] allele also increased the expression of CCDC92 in subcutaneous adipose tissue (Supplementary Table 6 ) in eQTL analyses conducted in the MuTHER Consortium and GTEx 10, 11 , suggesting a possible candidate gene for the association.
We sought to reduce our list to a subset of loci that colocalized the T2D and CHD associations to a single underlying genetic risk variant by conducting formal colocalization analyses (Online Methods). Eight of these 19 loci met this criterion, and at 7 of those 8 loci the risk allele for T2D also increased the risk for CHD ( Table 3) . This included loci with known associations with T2D (TCF7L2, HNF1A, CTRB1, and CTRB2) as well as previously unreported T2D loci reported here (MIR17HG and CCDC92) or known association with
Figure 1 A circular Manhattan plot summarizing the association results for the T2D scan. Black, previously established T2D loci; red, previously unreported T2D loci from trans-ancestry meta-analysis; blue, previously unreported T2D loci from European-only meta-analysis; green, previously unreported T2D locus discovered from the bivariate scan with additional support from replication.
CHD (MRAS and ZC3HC1).
Interestingly, this set of directionally consistent loci included coding variants in two genes encoding transcription factors: the missense variant(s) p.Ile27Leu in HNF1A and p.Arg326His in ZC3HC1. At the APOE locus, where the effect of association for T2D and CHD risk was opposite, localization was observed at rs4420638, but the tagging among the lead sentinel SNPs was incomplete, making it challenging to distinguish between multiple conditionally independent variant associations with both traits versus partial tagging of a single, common association. At the IRS1 locus, while we found rs7578326 to be associated with both T2D and CHD (P < 5 × 10 −8 ), formal colocalization analyses failed to identify a single underlying genetic risk factor for the two outcomes at this locus. Next, we used biomarker data to help understand the mechanisms linking T2D and CHD at two new loci discovered through bivariate scan, MIR17HG and CCDC92. The region around CCDC92 segregates numerous cardiometabolic trait associations, including T2D (rs1727313) 9 , HDL-C (rs4759375 and rs838880), triglycerides (rs4765127) 17 , and waist-hip ratio adjusted for BMI (rs4765219) 18 . However, variants in these previous reports were not strongly linked to our sentinel SNP (r 2 < 0.02 in all cases). The risk variant for T2D-CHD at the CCDC92 locus also decreased HDL-C levels (fixedeffects meta-analysis P = 2.2 × 10 −9 ) in analyses by the Global Lipids Genetics Consortium (GLGC) 17 ; this variant was in partial linkage with a variant (rs10773049; r 2 = 0.6 and 0.3 in Europe and South Asia, respectively) previously known for association with BMI. MIR17HG appeared to harbor only modest associations with HDL (fixed-effects meta-analysis P = 1.3 × 10 −4 ), fasting insulin levels (P = 6.4 × 10 −4 ), and homeostatic model assessment of insulin resistance (HOMA-IR; P = 7.9 × 10 −4 ).
We also examined association at APOE where the T2D risk allele was associated with decreased CHD risk. The T2D risk allele was also found associated with increased HDL-C (fixed-effects meta-analysis P = 1.72 × 10 −21 ), decreased LDL cholesterol (LDL-C; P = 1.51 × 10 −178 ), decreased total cholesterol (P = 1.14 × 10 −149 ), decreased triglycerides (P = 1.55 × 10 −14 ), reduced LDL particle size (P = 3.80 × 10 −11 ), increased waist-hip ratio (BMI adjusted; P = 1.80 × 10 −6 ), and increased risk of neovascular disease (P = 2.78 × 10 −8 ).
Joint T2D-CHD associations highlight new pathways
We next aimed to identify a subset of highly connected loci that indicate unidentified pathways that were jointly related to T2D and CHD. To achieve this, we used results from our bivariate T2D-CHD association scan and pruned SNPs for LD to obtain a set of unlinked regions across the genome (r 2 < 0.05). From this list, we selected 299 LD-independent SNPs that were found to be associated with T2D and CHD in our bivariate scan (P < 0.001; Supplementary Tables 17 and 18) and sought to prioritize candidate genes implicated in the association using the text-mining approach GRAIL 19 . Seventy-nine of 299 regions were found to have prioritized specific genes in associated intervals (GRAIL P < 0.05), significantly more overall than expected (26.4%; binomial test P < 1 × 10 −34 ). Next, protein-protein interaction connectivity analysis among these 79 genes 20 demonstrated more direct and indirect connections than expected (permuted P < 1 × 10 −4 ; Online Methods), thus motivating us to focus on this subset for further analysis. Several plausible candidates from this list emerged, including the hepatic glucose transporter gene SLC2A2, the adipocyte fatty-acid-binding protein gene FABP4 (aP2), LPIN1 (lipin-1), PPARGC1B (PGC-1β), and the free fatty acid receptor 1 gene FFAR1, among others (Supplementary Table 18 ). Chr., chromosome; EA, effect allele; NEA, non-effect allele; OR, odds ratio; CI, confidence interval; BVN, bivariate normal distribution of T2D and CHD statistics. Position is under hg19.
A r t i c l e s
We next performed ontology analysis on the set of 79 genes that emerged from the T2D-CHD bivariate scan for connectivity 21 . To compare our findings, we also conducted similar ontological analysis on loci identified for T2D or CHD in previous GWAS for each of these traits. As expected, ontological analysis of established T2D loci alone indicated robust enrichment of diabetes, hyperglycemia, and insulin resistance disease annotations (enrichment test P < 1 × 10 −55 ), as well as enrichment for pathways related to insulin secretion and transport, glucose homeostasis, and pancreas development (all P < 1 × 10 −9 ). Also as expected, ontological analysis of CHD loci alone demonstrated robust enrichment of disease annotations related to coronary disease, myocardial infarction, and arteriosclerosis (P < 1 × 10 −36 ), as well as enrichment for pathways related to lipid homeostasis and cholesterol transport (P < 1 × 10 −8 ). As expected, analysis of the 79 gene intervals associated with T2D and CHD identified loci that were also modestly enriched for disease ontologies related to vascular resistance (P < 1 × 10 −12 ), T2D, cardiovascular disease, fatty liver, obesity, gestational hypertension, and pre-eclampsia (all P < 1 × 10 −5 ), as well as cancer (P < 1 × 10 −9 ). In contrast to the pathways described above, we also observed enrichment for additional pathways related to cardiovascular system development, cell signaling, signal transduction, regulation of phosphorylation, and transmembrane receptor protein kinase signaling among the categories (adjusted P < 1 × 10 −7 ) (Supplementary Fig. 9 ).
DISCUSSION
We report the discovery of 16 new loci for T2D using discovery and replication studies in 265,678 participants. Using ExomeChip data, we were able to identify a coding variant that was more strongly associated with T2D risk than the corresponding noncoding variant. Using additional data on 260,365 participants, we report a new locus for CHD and identify genetic loci that are shared by T2D and CHD, of which a subset colocalized to the same genetic variant (for example, CCDC92, MIR17HG, HNF1A, ZC3HC1, and APOE; Table 3 ). Finally, using a bivariate scan for T2D and CHD together, genetic association data pointed to new pathways that are implicated in the etiology of both the disease outcomes.
Many of the loci discovered in the current meta-analyses suggest new T2D biology or confirm pathways previously implicated in T2D. For instance, MIR17HG, KL, and BCL2L11 have been shown to be involved in cell survival, apoptosis, and cellular aging, respectively [22] [23] [24] . Genetic variants near KL have also been shown to be associated with fasting glucose levels as well 25 . TMEM18 is involved in cellular migration; HLA-DR5 and CMIP have crucial roles in immune-mediated responses and have been implicated in various immunological disorders 26, 27 . Genetic variation at the HLA locus (rs9272346) has previously been implicated in type 1 diabetes (T1D); however, we did not find any evidence of association of rs9272346 with T2D in our meta-analyses. Additionally, rs9272346 was not in LD with the T2D sentinel SNP (rs2050188) at this locus (r 2 = 0.06 in Europe and r 2 = 0.01 in South Asian). However, rs7111341 has previously been reported as a risk factor for T1D 28 . We found that rs7111341[T] is associated with increased risk for T2D but decreased risk for T1D, a similar pattern of association to a previously established association (rs7202877, near CTRB1).
The contrasting associations of APOE with T2D and CHD were challenging to interpret. APOE encodes apolipoprotein E found in the chylomicron and intermediate-density lipoproteins (IDLs). Genetic variation at the APOE locus is associated with major lipids and CHD 6, 17 . Here the T2D risk variant was associated with decreased CHD risk and LDL-C and with reduced LDL particle size. These observations are consistent with recent studies indicating that reduction in levels of LDL-C, a major CHD risk factor, may confer a higher, but modest risk of T2D. Evidence from a meta-analysis of randomized controlled trials has shown that reduction of LDL-C by statin treatment, as compared to placebo, led to a higher but a very small absolute risk of T2D 29 . Moreover, genetic variants associated with reduced expression of HMG-CoA reductase, the target of statins, and reduced LDL-C levels have been shown to be associated with increased risk of T2D 30 . Also, two MR studies concluded that genetically mediated decreases in LDL-C associated with a higher risk of T2D 31, 32 . Furthermore, it has been shown that genetic variants in the PCSK9 gene that lower LDL-C levels are associated with a higher risk of T2D, fasting glucose concentration, body weight, and waist-hip ratio 33 . In contrast to the findings from our overall meta-analyses, these results suggest that LDL-C may represent one of a small subset of discrete pathways that display opposing associations for the two outcomes. These findings underscore how human genetics can help focus future investigations on T2D therapeutics that have either neutral or beneficial effects on vascular outcomes.
The collection of 79 regions identified through our joint T2D-CHD bivariate scan involves targets of existing drugs. These includes icosapent, a polyunsaturated fatty acid found in fish oil that is an FFAR1 and PPARG agonist and a COX1/COX2 inhibitor 34 . The ANCHOR trial showed that icosapent ethyl, marketed as the drug Vascepa, has efficacy in lowering triglycerides in patients with high triglyceride levels 35 as well as non-HDL-C and HDL-C 36 . A second plausible candidate gene is FABP4 (encoding the adipocyte fatty-acid-binding protein; also known as aP2). Mouse models deficient in aP2 display protection against atherosclerosis and antidiabetic phenotypes [37] [38] [39] . Moreover, small-molecule inhibition of aP2 has been shown to reduce atherosclerosis, glucose and insulin levels, and triglycerides in a mouse model 40 ; inhibition of this pathway through a monoclonal antibody also appears to be efficacious in mouse models 41 .
Careful evaluation of the pathways or biological processes where T2D, CHD, and related traits overlap could help to highlight new avenues for therapeutic targeting. First, using gene discovery and biomarker studies, we have identified new pathways, outside of the established glucose and cholesterol homeostatic networks, that could be investigated in more detail. Second, we have found that some genetic variants associated with T2D singly or in aggregate are enriched for associations with CHD. With one exception (pathways involving LDL-C), genetic pathways that increase T2D risk tend to overall increase CHD risk. Hence, existing or future therapeutic programs designed for the prevention of T2D could be better guided by evidence from genetic studies, to prioritize targets that have either neutral or directionally consistent effects on vascular outcomes. Overall, identification of genetic loci associated with both T2D and CHD risk in a directionally consistent manner could provide therapeutic opportunities to lower the risk of both outcomes.
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ONLINE METHODS
Study subjects. In the discovery phase, we performed meta-analysis on data from eight different studies; four studies (PROMIS, RACE, BRAVE, and EPIDREAM) include participants of South Asian origin living in Pakistan, Bangladesh, and Canada and four studies (FINRISK, MedStar, MDC, and PennCATH) include subjects of European origin (Supplementary Table 1 and Supplementary Note). GWAS/Metabochip data and information on T2D risk were available on 48,437 individuals (13,525 T2D cases and 34,912 controls) from these eight studies. We further used published data from the DIAGRAM Consortium and conducted combined discovery analysis on 198,258 participants (48, 365 T2D cases and 149,893 controls) . Characteristics of the participants and information on genotyping arrays and imputation are summarized in Supplementary Tables 1-3 . Replication studies were completed in participants enrolled in the LOLIPOP, SINDI, SDS, MSSE, TAICHI, and BBJ studies (Supplementary Table 1) , collectively composed of 67,420 individuals (24,972 cases and 42,448 controls) who were of South Asian (n = 13,960; 4,587 T2D cases and 9,373 controls), European (n = 2,479; 387 T2D cases and 2,092 controls), and East Asian (n = 50,981; 19,998 T2D cases and 30,983 controls) descent. Hence, our combined discovery and replication analyses included 265,678 participants (73,337 T2D cases and 192,341 controls). Further details of the contributing cohorts and characteristics of the participants are provided in Supplementary Table 1 and the Supplementary Note.
Institutional review boards and informed consent. All participating studies were approved by the relevant local institutional review boards. All participants enrolled in each of the participating studies provided informed consent.
Genotyping and quality control in the discovery stage. All studies used a high-density genotyping array (GWAS/Metabochip) (Supplementary Table 2 and Supplementary Note). Quality control procedures were performed for each individual study. Details on study-specific quality control are provided in Supplementary Table 2 . Each study individually assessed and controlled for any population stratification using principal-component analysis.
Imputation.
In all studies, the genomic locations of all variants were first harmonized using NCBI Build 37/UCSC hg19 coordinates. Only studies that contributed GWAS data underwent imputation. Imputation of genotypes across the genome was computed using data from the 1000 Genomes Project (phase 1 integrated release 3, March 2012) 43 . Imputed SNPs were removed if they had (i) a minor allele frequency (MAF) of <0.01; (ii) an info score of <0.90; or (iii) an average maximum posterior call <0.90. Supplementary Table 2 provides further details on the imputation protocol used by each of the participating studies.
Statistical analysis in the discovery stage. To test for an association between each SNP and risk of T2D, a logistic regression model was computed with adjustment for age, sex, and the first study-specific principal components using SNPTEST 44 . SNPs were modeled under an additive genetic model, and imputation uncertainty was accounted for under an allele dosage approach. Inflation of association statistics was assessed within each study by the genomic control method (Supplementary Fig. 1 and Supplementary Table 3) . Variants that were retained in at least two studies were subjected to meta-analysis using the weighted z-score method implemented in METAL 45 . Heterogeneity was assessed by Cochran's Q statistic and the I 2 heterogeneity index. Pairwise LD between SNPs was assessed and visualized using the 1000 Genomes European reference panel 43 . Regional association plots were visualized using LocusZoom software. After removing regions harboring known loci, the top associated SNP and one or more SNPs based on LD with the lead variant found in association with any of the above phenotypes (P < 5 × 10 −6 ) were selected for the replication studies.
Analyses in the replication stage. Studies that participated in the replication stage had conducted genotyping on GWAS or Metabochip arrays. The association of SNPs with T2D was calculated separately using a trend test, with heterogeneity between studies assessed using Cochran's Q statistic. Metaanalysis was then conducted using the weighted z-score method implemented in METAL to combine the results across all replication studies and with the discovery stage. For the combined analysis of discovery and replication data, genome-wide significance was inferred at P < 5 × 10 −8 .
eQTL and functional prioritization. To determine whether the identified risk variants influence expression of any nearby genes, we accessed a variety of sources, including (i) GTEx cis-eQTL data in all available tissues, including liver, brain, endothelial cells, and whole blood 10 , and (ii) cis-eQTL data for adipose, lymphoblastoid cell lines, and skin from the MuTHER Consortium 11 .
ExomeChip analysis. To assess whether there are coding variants associated with T2D in the proximity of the newly discovered sentinel T2D SNPs, we performed an ExomeChip-based meta-analysis in four studies (PROMIS, BRAVE, CIHDS-CGPS, and PROSPER) in the ±500-kb regions centered on the sentinel T2D SNPs. For all the studies, genotyping and quality control were carried out centrally in Cambridge, UK. In each study, samples with extreme intensity values and outlying plates or arrays were removed before genotype calling. Genotype calling was initially performed with optiCall. Samples with a call rate (CR) less than (mean CR -3 s.d.) were removed before postprocessing optiCall calls with zCall. Scanner-specific Z-values (calculated using the 1,000 samples with the highest optiCall CR) were adopted as they gave the best global concordance within each batch. Rare variants (optiCall, MAF < 0.05) were then postprocessed with zCall using the scanner-specific Z-values. Within each genotyping batch, variants were removed if variant CR was <0.97 or if Hardy-Weinberg equilibrium P value was <1 × 10 −6 for common variants or <1 × 10 −15 for rare variants (MAF < 0.05). Variants within each genotyping batch were aligned to the human genome reference sequence plus strand, and the standardized files were used for sample quality control. Samples were excluded from each batch or study if sample heterozygosity was >±3 s.d. from the mean heterogeneity or sample call rate was >3 s.d. from the mean call rate. Variants were further selected on the basis of stringent quality control thresholds (CR < 0.99, Hardy-Weinberg equilibrium P < 1 × 10 −4 , MAF > 0.05) and LD pruned (r 2 < 0.2) for principal-component analysis and kinship calculations. Duplicates within each collection (kinship coefficient > 0.45) and ancestral outliers identified by principal-component analysis were removed. Samples and variants that failed quality control were removed from individual batches. Where studies were analyzed in multiple batches, the batches were combined and any single-nucleotide variants (SNVs) out of Hardy-Weinberg equilibrium across the study were removed.
Study-specific analyses were conducted using RAREMETALWORKER 46,47 incorporating the kinship matrix and adjusting for age and sex. In each study, variants with minor allele count (MAC) <10 were removed before metaanalysis. Meta-analysis was performed in METAL. In the meta-analysis, the sample-size-weighted approach was used to estimate P values and an inversevariance-weighted approach was used to calculate pooled effect estimates and corresponding standard errors. Study-specific information is provided in Supplementary Table 19 .
Phenome/biomarker scan analyses. We downloaded online-available GWAS data from 12 consortia for 70 traits (Supplementary Table 9 ) and harmonized genome positions to Build37/hg19. We then performed a lookup for the newly discovered T2D SNPs using these harmonized data sets. We also performed a phenotypic scan for the same new T2D SNPs across 105 biomarkers measured in the PROMIS participants using a linear regression model adjusted for the first five principal components (Supplementary Table 10 ). We used a Bonferroni-adjusted P-value cutoff of 1.8 × 10 −5 (= 0.05/175 traits/16 SNPs) to declare statistical significance.
Coronary heart disease meta-analysis. We assembled 56,354 samples of European, East Asian, and South Asian ancestry genotyped on the CardioMetabochip to identify genetic determinants of CHD. These results were combined with those reported by CARDIoGRAMplusC4D to yield analyses comprising 260,365 subjects (90,831 CHD cases) for CHD. Additional new CHD studies comprised 16,093 CHD cases and 16,616 unaffected individuals: EPIC-CVD study, a case-cohort study recruited across ten European countries; the Copenhagen City Heart Study (CCHS), the Copenhagen Ischemic Heart Disease Study (CIHDS), and the Copenhagen General Population Study (CGPS) all recruited within Copenhagen, Denmark; the South Asian studies comprised up to 7,654 CHD cases and 7,014 controls from the Pakistan Risk of Myocardial Infarction Study (PROMIS), a case-control study that recruited samples from nine sites in Pakistan, and the Bangladesh Risk of Acute Vascular Events (BRAVE) study based in Dhaka, Bangladesh; the East Asian studies comprised 4,129 CHD cases and 6,369 controls recruited from seven studies across Taiwan that collectively make up the TAIwan metaboCHIp (TAICHI) Consortium. Samples from EPIC-CVD, CCHS, CIHDS, CGPS, BRAVE, and PROMIS were all genotyped on a customized version of the Illumina CardioMetabochip, referred to as Metabochip+, in two Illumina-certified laboratories located in Cambridge, UK, and Copenhagen, Denmark. TAICHI samples were genotyped using the latest version of the CardioMetabochip. For each study, samples were removed if they had CR <0.97, had average heterozygosity >±3 s.d. from the overall mean heterozygosity, or the genotypic sex did not match the reported sex. One of each pair of duplicate samples and first-degree relatives (identified by a kinship coefficient >0.2) was removed. CardioMetabochip data were also obtained from the Women's Health Initiative Study and the ARIC study; the two studies underwent the same quality control as described for the TAICHI study. Across all studies, SNP exclusions were based on MAF < 0.01, P < 1 × 10 −6 for Hardy-Weinberg equilibrium, or CR < 0.97. CARDIoGRAMplusC4D Consortium data were obtained online (see URLs). Only non-overlapping samples were used for meta-analyses. Fixedeffects inverse-variance-weighted meta-analysis was used to combine the effects across studies in METAL 45 .
Genetic risk score analysis. We used a two-sample MR method 48 to estimate effects for a multi-SNP genetic instrument by using summary statistics. This method has previously been validated to infer causal effects (odds ratios) and associated standard error 49 . Briefly, association data for both T2D and CHD were obtained using data from two separate genome-wide meta-analyses. For T2D, we used the data from the current meta-analyses, whereas we used data from the most recent CHD meta-analyses as described in the Supplementary Note. Using sentinel SNPs for all established T2D associations, we identified a set of variants (n = 16) exclusively associated with T2D by screening against the GWAS catalog of publicly available data 50 for anthropometric traits (BMI, waist-hip ratio, waist circumference, waist-hip ratio adjusted for BMI, waist circumference adjusted for BMI, and hip), glucose/insulin or MAGIC traits (fasting glucose, 2-h glucose, fasting insulin, and proinsulin levels), blood lipids (HDL-C, LDL-C, and triglycerides), and blood pressure (systolic and diastolic). We next attempted to group the remaining pleiotropic T2D SNPs into different categories on the basis of their observed associations for various cardiometabolic intermediate traits (P < 0.01). These groupings included (i) variants associated with glucose/insulin traits only (n = 13), (ii) variants associated with triglycerides/HDL-C and waist circumference/waist-hip ratio but not glucose/insulin, blood pressure, LDL-C, or BMI (n = 6), (iii) variants associated with triglycerides/HDL-C and obesity/anthropometric traits but not glucose/insulin, blood pressure, or LDL-C (n = 6), (iv) variants associated with triglycerides/HDL-C, blood pressure, and BMI but not glucose/insulin or LDL-C (n = 8), and (v) variants associated with triglycerides/HDL-C, blood pressure, BMI, and glucose/insulin but not blood pressure or LDL-C (n = 24) (Supplementary Table 12 ). Established T2D SNPs that did not fall into any of these categories were excluded. Heterogeneity in odds ratios was assessed via Cochran's Q test for heterogeneity.
T2D and CHD enrichment analysis. We used a binomial distribution with baseline enrichment probability P b to derive the density for the test statistic E ~ Binomial(n, P b ), where n is the number of SNPs in a variant set. E is the number of SNPs with a directionally consistent effect on T2D and CHD (the allele that increases the risk for T2D also increases the risk for CHD). Using SNPs that were not associated with T2D or CHD (P ≥ 0.05 for T2D and CHD), we calculated the percentage of SNPs with a directionally consistent effect in T2D and CHD and used this as an estimate for P b . We then performed the enrichment analysis in two variant sets: (i) the variant set with all variants available and (ii) the variant set with LD-clumped variants. The results are shown in Supplementary Table 15. In the LD clumping procedure, the SNPs with more significant T2D P values were retained as seeds and the other SNPs that were in LD (r 2 > 0.1 based on data from the 1000 Genomes Project (phase 3, v5 variant set)) with the seed SNPs were removed 43 .
Estimating the T2D-CHD bivariate normal density. To establish the T2D-CHD bivariate normal density, we used all variants that we identified in our analyses on T2D and CHD; we further pruned them for LD with 1000 Genomes Project data (Phase 3, v5 variant set) to r 2 ≤ 0.1 using PLINK 51, 52 . The reference and alternate alleles of the variants that survived LD pruning were retrieved from the same 1000 Genomes VCF file used for pruning, and the variants' effects on CHD and T2D were aligned to their reference alleles. The statistics used to estimate the bivariate normal density were produced using the following formula:
where Φ −1 is the inverse-cumulative distribution function of the standard normal distribution, P CHD and P T2D are the P values for CHD and T2D, respectively, and β CHD and β T2D are the effect sizes of the reference allele on CHD and T2D, respectively. Because a successful estimation of the bivariate distribution depends on both positive and negative Z-scores, we used the signs of the corresponding effect estimates (β/|β|) to determine the signs of Z CHD and Z T2D . The distributions of Z CHD and Z T2D are shown in Supplementary Figure  5 . Parameters for the bivariate normal density were estimated using the mvn. ub() function in the R package miscF. The estimated bivariate normal density has the following parameter values. 
where N 2 (µ, Σ) denotes a bivariate normal distribution with a vector of means µ and variance-covariance matrix Σ, and c 2 2 is the chi-squared distribution with 2 degrees of freedom. Using Y as the test statistic, we performed a twodegree-of-freedom test on Z = (Z CHD , Z T2D ), and our null hypothesis was that a SNP was not associated with either of the two traits. Supplementary Figure 5 depicts the rejection region of the two-degree-of-freedom test.
Conditional analysis for CCDC92. We performed approximate conditional analysis for the CCDC92 locus using the software package GCTA 53 . We used the summary meta-analysis data for our primary T2D and CHD scans (before replication) as data input from each continental group (European, South Asian, and East Asian). As the reference input, we used population data from the 1000 Genomes Project (version 3) matching the continental ancestry for the respective conditional analysis. We then conditioned on rs825476-the lead SNP associated with CHD and T2D-for each continental group. We combined the summary results from each continental group via inverse-weighted fixedeffects meta-analysis. LocusZoom plots for these conditional meta-analysis association results are presented in Supplementary Figure 8 .
Colocalization analysis. To determine whether the T2D and CHD association signals colocalized to the same genetic variant, we used the R package coloc. For each of the 19 loci that met our T2D-CHD association criteria, we obtained association data from all SNPs within 500 kb of the sentinel bivariate associated SNP (Supplementary Table 16 ). From there, we used the coloc.abf() function to calculate the probability that both traits are associated and share a single causal variant (H 4 ), using the P values from the overall inverse-variance fixed-effects meta-analysis for T2D (without replication) and CHD, the overall case-control sample sizes for both scans, and the allele frequencies for the variant based on all 1000 Genomes data (version 3). We call variants colocalized if the H 4 colocalization probability was greater than 0.5.
Selection of loci for connectivity and ontology analyses. For T2D, we used the previously reported loci 5 (n = 88) and the loci discovered in this report (n = 16). For CHD, we used the previously reported loci described in the most recent report published by the CARDIoGRAMplusC4D Consortium (n = 58) 6 . Prioritization of genes from this list of established loci for T2D and CHD (Supplementary Table 17 ) was based on evidence from monogenic association with disease 53 , coding mutations in nearby genes, functional evidence implicating genes, or the gene nearest to the sentinel SNP. For T2D-CHD associations arising from our bivariate scan, we first pruned the data set for LD (r 2 < 0.1). We further selected 299 LD-independent SNPs that were found to be associated with T2D and CHD with P < 0.001 in our bivariate scan and used them to identify underlying candidate genes using GRAIL 19 . For protein-protein interaction connectivity analysis, we used DAPPLE 20 on the 79 loci that were found to be significant in GRAIL 19 . Empirical significance for excess connectivity in protein-protein interactions was assessed by 10,000 permutations.
Ontology analysis and drug target annotations. We used the online tool WebGestalt 21 to perform ontology enrichment analysis. For analysis of the query loci, we nominated genes (n = 79) that were prioritized from text mining (GRAIL P < 0.05). We also performed ontology analyses using separate gene lists for T2D (n = 104) and CHD (n = 58) loci separately. The hypergeometric distribution was used to assess significance, and adjustment for multiple testing was controlled for using the Benjamini-Hochberg procedure 54 implemented in WebGestalt 21 .
Data availability. Summary GWAS estimates for the T2D meta-analysis and bivariate summary data, respectively, are publicly available in the following files: http://www.med.upenn.edu/ccebfiles//t2d_meta_cleaned.zip, and
